Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SsK12 + liposomal glutathione
- Development stage
- Unknown
- Lead developer
- General Hospital of Western Theater Command of PLA
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
SsK12 + liposomal glutathione (SsK12@Lip@GSH) is an investigational oral probiotic formulation developed by the General Hospital of Western Theater Command for the prevention and treatment of radiation-induced oral mucositis (RIOM) in patients with head and neck malignancies. The formulation consists of the probiotic strain *Streptococcus salivarius* K12 (SsK12) encapsulated within liposomes and combined with glutathione (GSH). This liposomal delivery system is designed to enhance the stability of the probiotic and provide free radical scavenging activity to combat oxidative stress. Additionally, the glutathione component facilitates targeted delivery to the oral mucosa by exploiting the overexpression of GSH transporters at sites of radiation damage. Clinical results from a Phase 1 study (NCT06446180) indicate that the treatment is well-tolerated and may reduce the severity of oral mucositis and prevent radiotherapy interruptions.
- Other names
- Streptococcus salivarius K12 encapsulated in liposomes with glutathioneSsK12-Lip-GSHSsK-12-Lip-GSHSsK 12-Lip-GSH
02
Targets
GSH (Glutathione synthesis / redox)
Beyond the preview
Go deeper on SsK12 + liposomal glutathione.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SsK12 + liposomal glutathione.